Genomic attributes of prostate cancer across primary and metastatic noncastrate and castrate resistant disease states: a next generation sequencing study of 183 patients

Surendra Dasari; Michael R. McCarthy; Antonina A. Wojcik; Beth A. Pitel; Arpan Samaddar; Burak Tekin; Rumeal D. Whaley; Aditya Raghunathan; Loren Herrera Hernandez; Rafael E. Jimenez; Brad J. Stish; R. Houston Thompson; Bradley C. Leibovich; Stephen A. Boorjian; R. Jeffrey Karnes; Daniel S. Childs; J. Fernando Quevedo; Eugene D. Kwon; Lance C. Pagliaro; Brian A. Costello; Kevin C. Halling; John C. Cheville; Benjamin R. Kipp; Sounak Gupta

doi:10.1038/s41391-024-00814-2

Genomic attributes of prostate cancer across primary and metastatic noncastrate and castrate resistant disease states: a next generation sequencing study of 183 patients

Surendra Dasari, Michael R. McCarthy, Antonina A. Wojcik, Beth A. Pitel, Arpan Samaddar, Burak Tekin, Rumeal D. Whaley, Aditya Raghunathan, Loren Herrera Hernandez, Rafael E. Jimenez, Brad J. Stish, R. Houston Thompson, Bradley C. Leibovich, Stephen A. Boorjian, R. Jeffrey Karnes, Daniel S. Childs, J. Fernando Quevedo, Eugene D. Kwon, Lance C. Pagliaro, Brian A. CostelloKevin C. Halling, John C. Cheville, Benjamin R. Kipp, Sounak Gupta

Research output: Contribution to journal › Article › peer-review

Abstract

Primary prostatic adenocarcinoma (pPC) undergoes genomic evolution secondary to therapy-related selection pressures as it transitions to metastatic noncastrate (mNC-PC) and castrate resistant (mCR-PC) disease. Next generation sequencing results were evaluated for pPC (n = 97), locally advanced disease (involving urinary bladder/rectum, n = 12), mNC-PC (n = 21), and mCR-PC (n = 54). We identified enrichment of TP53 alterations in high-grade pPC, TP53/RB1 alterations in HGNE disease, and AR alterations in metastatic and castrate resistant disease. Actionable alterations (MSI-H phenotype and HRR genes) were identified in approximately a fifth of all cases. These results help elucidate the landscape of genomic alterations across the clinical spectrum of prostate cancer.

Original language	English (US)
Journal	Prostate Cancer and Prostatic Diseases
DOIs	https://doi.org/10.1038/s41391-024-00814-2
State	Accepted/In press - 2024

ASJC Scopus subject areas

Oncology
Urology
Cancer Research

Access to Document

10.1038/s41391-024-00814-2

Cite this

Dasari, S., McCarthy, M. R., Wojcik, A. A., Pitel, B. A., Samaddar, A., Tekin, B., Whaley, R. D., Raghunathan, A., Hernandez, L. H., Jimenez, R. E., Stish, B. J., Thompson, R. H., Leibovich, B. C., Boorjian, S. A., Jeffrey Karnes, R., Childs, D. S., Quevedo, J. F., Kwon, E. D., Pagliaro, L. C., ... Gupta, S. (Accepted/In press). Genomic attributes of prostate cancer across primary and metastatic noncastrate and castrate resistant disease states: a next generation sequencing study of 183 patients. Prostate Cancer and Prostatic Diseases. https://doi.org/10.1038/s41391-024-00814-2

Dasari, S, McCarthy, MR, Wojcik, AA, Pitel, BA, Samaddar, A, Tekin, B, Whaley, RD, Raghunathan, A, Hernandez, LH, Jimenez, RE, Stish, BJ, Thompson, RH, Leibovich, BC, Boorjian, SA, Jeffrey Karnes, R, Childs, DS, Quevedo, JF, Kwon, ED, Pagliaro, LC, Costello, BA, Halling, KC, Cheville, JC, Kipp, BR & Gupta, S 2024, 'Genomic attributes of prostate cancer across primary and metastatic noncastrate and castrate resistant disease states: a next generation sequencing study of 183 patients', Prostate Cancer and Prostatic Diseases. https://doi.org/10.1038/s41391-024-00814-2

@article{aa1c61fa34d6476ea475ce9bd12fdf8e,

title = "Genomic attributes of prostate cancer across primary and metastatic noncastrate and castrate resistant disease states: a next generation sequencing study of 183 patients",

abstract = "Primary prostatic adenocarcinoma (pPC) undergoes genomic evolution secondary to therapy-related selection pressures as it transitions to metastatic noncastrate (mNC-PC) and castrate resistant (mCR-PC) disease. Next generation sequencing results were evaluated for pPC (n = 97), locally advanced disease (involving urinary bladder/rectum, n = 12), mNC-PC (n = 21), and mCR-PC (n = 54). We identified enrichment of TP53 alterations in high-grade pPC, TP53/RB1 alterations in HGNE disease, and AR alterations in metastatic and castrate resistant disease. Actionable alterations (MSI-H phenotype and HRR genes) were identified in approximately a fifth of all cases. These results help elucidate the landscape of genomic alterations across the clinical spectrum of prostate cancer.",

author = "Surendra Dasari and McCarthy, {Michael R.} and Wojcik, {Antonina A.} and Pitel, {Beth A.} and Arpan Samaddar and Burak Tekin and Whaley, {Rumeal D.} and Aditya Raghunathan and Hernandez, {Loren Herrera} and Jimenez, {Rafael E.} and Stish, {Brad J.} and Thompson, {R. Houston} and Leibovich, {Bradley C.} and Boorjian, {Stephen A.} and {Jeffrey Karnes}, R. and Childs, {Daniel S.} and Quevedo, {J. Fernando} and Kwon, {Eugene D.} and Pagliaro, {Lance C.} and Costello, {Brian A.} and Halling, {Kevin C.} and Cheville, {John C.} and Kipp, {Benjamin R.} and Sounak Gupta",

note = "Publisher Copyright: {\textcopyright} The Author(s), under exclusive licence to Springer Nature Limited 2024.",

year = "2024",

doi = "10.1038/s41391-024-00814-2",

language = "English (US)",

journal = "Prostate Cancer and Prostatic Diseases",

issn = "1365-7852",

publisher = "Springer Nature",

}

TY - JOUR

T1 - Genomic attributes of prostate cancer across primary and metastatic noncastrate and castrate resistant disease states

T2 - a next generation sequencing study of 183 patients

AU - Dasari, Surendra

AU - McCarthy, Michael R.

AU - Wojcik, Antonina A.

AU - Pitel, Beth A.

AU - Samaddar, Arpan

AU - Tekin, Burak

AU - Whaley, Rumeal D.

AU - Raghunathan, Aditya

AU - Hernandez, Loren Herrera

AU - Jimenez, Rafael E.

AU - Stish, Brad J.

AU - Thompson, R. Houston

AU - Leibovich, Bradley C.

AU - Boorjian, Stephen A.

AU - Jeffrey Karnes, R.

AU - Childs, Daniel S.

AU - Quevedo, J. Fernando

AU - Kwon, Eugene D.

AU - Pagliaro, Lance C.

AU - Costello, Brian A.

AU - Halling, Kevin C.

AU - Cheville, John C.

AU - Kipp, Benjamin R.

AU - Gupta, Sounak

PY - 2024

Y1 - 2024

N2 - Primary prostatic adenocarcinoma (pPC) undergoes genomic evolution secondary to therapy-related selection pressures as it transitions to metastatic noncastrate (mNC-PC) and castrate resistant (mCR-PC) disease. Next generation sequencing results were evaluated for pPC (n = 97), locally advanced disease (involving urinary bladder/rectum, n = 12), mNC-PC (n = 21), and mCR-PC (n = 54). We identified enrichment of TP53 alterations in high-grade pPC, TP53/RB1 alterations in HGNE disease, and AR alterations in metastatic and castrate resistant disease. Actionable alterations (MSI-H phenotype and HRR genes) were identified in approximately a fifth of all cases. These results help elucidate the landscape of genomic alterations across the clinical spectrum of prostate cancer.

AB - Primary prostatic adenocarcinoma (pPC) undergoes genomic evolution secondary to therapy-related selection pressures as it transitions to metastatic noncastrate (mNC-PC) and castrate resistant (mCR-PC) disease. Next generation sequencing results were evaluated for pPC (n = 97), locally advanced disease (involving urinary bladder/rectum, n = 12), mNC-PC (n = 21), and mCR-PC (n = 54). We identified enrichment of TP53 alterations in high-grade pPC, TP53/RB1 alterations in HGNE disease, and AR alterations in metastatic and castrate resistant disease. Actionable alterations (MSI-H phenotype and HRR genes) were identified in approximately a fifth of all cases. These results help elucidate the landscape of genomic alterations across the clinical spectrum of prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=85186178739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85186178739&partnerID=8YFLogxK

U2 - 10.1038/s41391-024-00814-2

DO - 10.1038/s41391-024-00814-2

M3 - Article

AN - SCOPUS:85186178739

SN - 1365-7852

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

ER -

Genomic attributes of prostate cancer across primary and metastatic noncastrate and castrate resistant disease states: a next generation sequencing study of 183 patients

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this